CNS disorders pharmaceutical Adamas files for a $69 million IPO

Comment

Shutterstock photo

Adamas Pharmaceuticals, which develops treatments for CNS disorders such as Parkinson's and Alzheimer's, filed on Wednesday with the SEC to raise up to $69 million in an initial public offering. The Emeryville, CA-based company, which was founded in 2000 and booked $71 million in sales for the fiscal year ended December 31, 2013, plans to list on the NASDAQ under the symbol ADMS. Adamas Pharmaceuticals initially filed confidentially on January 31, 2014. Credit Suisse and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com